AAPL   322.00 (+1.28%)
MSFT   182.79 (-0.26%)
GOOGL   1,435.63 (+0.15%)
AMZN   2,471.42 (+1.19%)
NVDA   351.98 (-0.84%)
CGC   16.49 (-5.50%)
BABA   206.37 (-0.49%)
MU   47.00 (-1.90%)
GE   6.72 (+2.28%)
T   31.13 (+0.87%)
F   5.86 (+2.81%)
DIS   118.90 (+1.36%)
BAC   24.69 (+2.36%)
AAPL   322.00 (+1.28%)
MSFT   182.79 (-0.26%)
GOOGL   1,435.63 (+0.15%)
AMZN   2,471.42 (+1.19%)
NVDA   351.98 (-0.84%)
CGC   16.49 (-5.50%)
BABA   206.37 (-0.49%)
MU   47.00 (-1.90%)
GE   6.72 (+2.28%)
T   31.13 (+0.87%)
F   5.86 (+2.81%)
DIS   118.90 (+1.36%)
BAC   24.69 (+2.36%)
AAPL   322.00 (+1.28%)
MSFT   182.79 (-0.26%)
GOOGL   1,435.63 (+0.15%)
AMZN   2,471.42 (+1.19%)
NVDA   351.98 (-0.84%)
CGC   16.49 (-5.50%)
BABA   206.37 (-0.49%)
MU   47.00 (-1.90%)
GE   6.72 (+2.28%)
T   31.13 (+0.87%)
F   5.86 (+2.81%)
DIS   118.90 (+1.36%)
BAC   24.69 (+2.36%)
AAPL   322.00 (+1.28%)
MSFT   182.79 (-0.26%)
GOOGL   1,435.63 (+0.15%)
AMZN   2,471.42 (+1.19%)
NVDA   351.98 (-0.84%)
CGC   16.49 (-5.50%)
BABA   206.37 (-0.49%)
MU   47.00 (-1.90%)
GE   6.72 (+2.28%)
T   31.13 (+0.87%)
F   5.86 (+2.81%)
DIS   118.90 (+1.36%)
BAC   24.69 (+2.36%)
Log in

ASX:CUVClinuvel Pharmaceuticals Stock Price, Forecast & News

A$23.00
+0.10 (+0.44 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$22.13
Now: A$23.00
A$23.04
50-Day Range
A$19.87
MA: A$21.97
A$23.35
52-Week Range
A$12.92
Now: A$23.00
A$45.88
Volume124,193 shs
Average VolumeN/A
Market Capitalization$1.14 billion
P/E Ratio75.91
Dividend Yield0.10%
BetaN/A
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited is headquartered in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9660 4900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.04 million
Cash FlowA$1.19 per share
Book ValueA$1.20 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.14 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive CUV News and Ratings via Email

Sign-up to receive the latest news and ratings for CUV and its competitors with MarketBeat's FREE daily newsletter.

Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions

How has Clinuvel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Clinuvel Pharmaceuticals' stock was trading at A$15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CUV shares have increased by 49.8% and is now trading at A$23.00. View which stocks have been most impacted by Coronavirus.

Has Clinuvel Pharmaceuticals been receiving favorable news coverage?

News coverage about CUV stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clinuvel Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutClinuvel Pharmaceuticals.

Who are some of Clinuvel Pharmaceuticals' key competitors?

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Worldpay (WP), REA Group (REA), CSL (CSL), Cochlear (COH) and Afterpay Touch Group (APT).

Who are Clinuvel Pharmaceuticals' key executives?

Clinuvel Pharmaceuticals' management team includes the following people:
  • Dr. Philippe Jacques Wolgen, CEO, MD & Director (Age 56)
  • Mr. Darren M. Keamy, CFO & Company Sec. (Age 46)
  • Dr. Dennis J. Wright BPharm, M.Sc., Ph.D., Acting Chief Scientific Officer
  • Lachlan Hay, Gen. Mang. of Europe

What is Clinuvel Pharmaceuticals' stock symbol?

Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV."

What is Clinuvel Pharmaceuticals' stock price today?

One share of CUV stock can currently be purchased for approximately A$23.00.

How big of a company is Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals has a market capitalization of $1.14 billion and generates $32.04 million in revenue each year.

What is Clinuvel Pharmaceuticals' official website?

The official website for Clinuvel Pharmaceuticals is www.clinuvel.com.

How can I contact Clinuvel Pharmaceuticals?

The company can be reached via phone at 61 3 9660 4900.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.